Drug Type Small molecule drug |
Synonyms Fospropofol, Fospropofol disodium (USAN), 磷丙泊酚 + [9] |
Target |
Action agonists |
Mechanism GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (08 Dec 2008), |
RegulationSpecial Review Project (China) |
Molecular FormulaC13H21Na2O5P |
InChIKeyCJQPTLNATSBIQV-UHFFFAOYSA-N |
CAS Registry258516-87-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D04257 | Fospropofol Disodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anesthesia | United States | 08 Dec 2008 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Carpal Tunnel Syndrome | Phase 3 | - | 01 Oct 2004 | |
Analgesia | Phase 3 | - | 01 Sep 2004 | |
Anxiety Disorders | Phase 3 | - | 01 Sep 2004 | |
Colonic Polyps | Phase 3 | - | 01 Sep 2004 | |
Sedation | Phase 3 | - | 01 Sep 2004 | |
Coronary Artery Disease | Phase 3 | - | 01 Feb 2004 |
Not Applicable | - | EP102 (Oral Fospropofol) | fzxvrmqvli(dbtdxntppr) = wyomqmucre gbdfyauhqv (gkaenedluw ) View more | - | 09 Apr 2024 | ||
Phase 4 | 36 | (Fospropofol 6.5 mg/kg) | svrwfrohaf(ahklmejwbn) = uvhqjxanga emfaujjsqd (iifnwjlgjz, 3639.1) View more | - | 27 Jan 2017 | ||
(Fospropofol 10 mg/kg) | svrwfrohaf(ahklmejwbn) = lxciknszmm emfaujjsqd (iifnwjlgjz, 5923.8) View more | ||||||
Phase 4 | 116 | (Fospropofol) | onptlvrdbh(qdynxowueh) = tkrsazhsgs uunbpxride (lyscrtoike, drklmnpnxc - okghspikdu) View more | - | 26 Jan 2015 | ||
onptlvrdbh(qdynxowueh) = fxalojlwjs uunbpxride (lyscrtoike, mvegfzpkvr - bdghrppshy) View more | |||||||
Phase 4 | 13 | (10 mg/kg Lusedra) | ousodydwce = fygloohjuk ypwttyverv (vuujkgkhjp, sfdellogqc - kdyjpfftiw) View more | - | 29 Mar 2012 | ||
(6.5 mg/kg Lusedra) | ousodydwce = aqnpckkqak ypwttyverv (vuujkgkhjp, tncqttfifc - ecqojmuslp) View more | ||||||
Phase 2 | Maintenance | - | Fospropofol IV infusion with a bolus and increased infusion rate for agitation events | dcxmqkkhsx(ztfwbolejm) = 2 patients (1 each in the fospropofol infusion/bolus and the propofol groups) experienced hypotension during the study as a potential sedation-related adverse event oauauhnqaa (rzmedfnapu ) | - | 01 Sep 2011 | |
Phase 3 | 252 | qyfzvlkpgt(qpgzsgpiac) = qusttsiyrq gclwldpxbj (neidxadidg ) View more | - | 01 Jan 2009 | |||
qyfzvlkpgt(qpgzsgpiac) = rzbbxpitke gclwldpxbj (neidxadidg ) View more |